Evidence map›Paper›PMID 33374342›Full record

ArticleVaccines2020

Interferon-α-Induced Dendritic Cells Generated with Human Platelet Lysate Exhibit Elevated Antigen Presenting Ability to Cytotoxic T Lymphocytes.

Ippei Date, Terutsugu Koya, Takuya Sakamoto, Misa Togi, Haruhiko Kawaguchi, Asuka Watanabe, Tomohisa Kato, Shigetaka Shimodaira

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. The Detection of Immunity against WT1 and SMAD4International journal of molecular sciences · 2022
    Article
  7. Platelet Derivatives and the Immunomodulation of Wound Healing.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ippei DateDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.
Terutsugu KoyaDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.
Takuya SakamotoDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.ORCID 0000-0003-2519-4510
Misa TogiDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.ORCID 0000-0002-7424-4548
Haruhiko KawaguchiDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.
Asuka WatanabeDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.
Tomohisa KatoMedical Research Institute, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.
Shigetaka ShimodairaDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku 920-0293, Japan.ORCID 0000-0002-6612-6912
Kanazawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the recent advancements of immune checkpoint inhibitors, there is considerable interest in cancer immunotherapy provided through dendritic cell (DC)-based vaccination. Although many studies have been conducted to determine the potency of DC vaccines against cancer, the clinical outcomes are not yet optimal, and further improvement is necessary. In this study, we evaluated the potential ability of human platelet lysate (HPL) to produce interferon-α-induced DCs (IFN-DCs). In the presence of HPL, IFN-DCs (HPL-IFN-DCs) displayed high viability, yield, and purity. Furthermore, HPL-IFN-DCs displayed increased CD14, CD56, and CCR7 expressions compared with IFN-DCs produced without HPL; HPL-IFN-DCs induced an extremely higher number of antigen-specific cytotoxic T lymphocytes (CTLs) than IFN-DCs, which was evaluated with a human leukocyte antigen (HLA)-restricted melanoma antigen recognized by T cells 1 (MART-1) peptide. Additionally, the endocytic and proteolytic activities of HPL-IFN-DCs were increased. Cytokine production of interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α was also elevated in HPL-IFN-DCs, which may account for the enhanced CTL, endocytic, and proteolytic activities. Our findings suggest that ex-vivo-generated HPL-IFN-DCs are a novel monocyte-derived type of DC with high endocytic and proteolytic activities, thus highlighting a unique strategy for DC-based immunotherapies.

Indexed as

cytotoxic T lymphocytedendritic cellsendocytosishuman platelet lysateimmunotherapyproteolytic activitytumor-associated antigensvaccine

Identifiers

PMID33374342
PMCPMC7823331
OpenAlexW3114838908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.